Publicacións nas que colabora con Pilar Nos Mateu (9)

2023

  1. I-CARE, a European Prospective Cohort Study Assessing Safety and Effectiveness of Biologics in Inflammatory Bowel Disease

    Clinical Gastroenterology and Hepatology, Vol. 21, Núm. 3, pp. 771-788.e10

  2. Should Inflammatory Bowel Disease Clinicians Provide Their Patients with e-Health Resources? Patients' and Professionals' Perspectives

    Telemedicine journal and e-health : the official journal of the American Telemedicine Association, Vol. 29, Núm. 10, pp. 1504-1513

2020

  1. The Harvey-Bradshaw Index Adapted to a Mobile Application Compared with In-Clinic Assessment: The MediCrohn Study

    Telemedicine and e-Health, Vol. 26, Núm. 1, pp. 80-88

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Quality of life during one year of postoperative prophylactic drug therapy after intestinal resection in Crohn's patients: Results of the APPRECIA trial

    Digestive and Liver Disease, Vol. 51, Núm. 4, pp. 529-535

2017

  1. Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial

    Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301

2015

  1. Fecal calprotectin in ileal Crohn's disease: Relationship with magnetic resonance enterography and a pathology score

    Inflammatory Bowel Diseases, Vol. 21, Núm. 7, pp. 1572-1579

2014

  1. 256 Is Fecal Calprotectin (FC) a Useful Tool for Screening MR-Enterography in Inflammatory Small Bowel Crohn's Disease (CD)?

    Gastroenterology, Vol. 146, Núm. 5, pp. S-61

  2. P272 Can fecal calprotectin (FC) predict activity in the MR-enterography in small bowel Crohn's disease (CD)?

    Journal of Crohn's and Colitis, Vol. 8, pp. S176-S177